1. Adams RA, Leon G, Miller NM, et al. Rifamycin antibiotics and the mechanisms of their failure. J Antibiot. 2021; 74: 786-798.
2. Maslow MJ, Portal-Celhay C. Rifamycins. In: Bennet JE, Dobin R, Blaser MJ (eds). Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th edition. 2019 (online)
3. Rothstein DM. Rifamycins, alone and in combination. Cold Spring Harb Perspect Med. 2016; 6: a027011.
4. Chen LF, Kaye D. Current use for old antibacterial agents: Polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am. 2009; 7523: 1053–1075.
5. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev. 2010; 23: 14–34.
6. Malenfant JH, Brewer TF. Rifampicin mono-resistant tuberculosis-A review of an uncommon but growing challenge for global tuberculosis control. Open Forum Infect Dis. 2021; 8: ofab018.
7. Li G, Zhang J, Guo Q, et al. Study of efflux pump gene expression in rifampicin-monoresistant Mycobacterium tuberculosis clinical isolates. J Antibiot. 2015; 68: 431–435.
8. WHO. Global tuberculosis report 2023. WHO institutional repository for information sharing. 2023. https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf?sequen-
ce=1
9. Sekaggya-Wiltshire C, Dooley KE. Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis. Expert Opin Drug Metab Toxicol. 2019;
15: 615-618.
10. California Department of Public Health, Rutgers Ernest Mario School of Pharmacy, Rutgers Global Tubercu- losis Institute, and the Curry International Tuberculosis Center. Rifamycin
drug-drug interactions: a guide for primary care providers treating latent tuberculosis infection. 2022. (pages 1-102). https://www.currytbcenter.ucsf.edu/sites/default/files/2022-12/Rifamy-
cin_2022.pdf
11. Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with
rifamycins. Clin Pharmacokinet. 2014; 53: 489-507.
12. T.C. Sağlık Bakanlığı Tüberküloz Tanı ve Tedavi Rehberi. 2. Baskı. Ankara, 2019.
13. Guidelines for the diagnosis, treatment and prevention of leprosy. World Health Organization, 2018. https://iris.who.int/bitstream/handle/10665/274127/9789290226383-eng.pdf?sequen-
ce=58#:~:text=Treatment%20of%20leprosy,12%20months%20for%20MB%20leprosy.
14. van de Beek D, Cabellos C, Dzupova O, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016; 22: S37-62.
15. Yu X, Jin Y, Zhou W, et al. Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome. Front Cell Infect Microbiol. 2022; 11:
761192.
16. Brenner DM, Sayuk GS. Current US Food and Drug Administration-approved pharmacologic therapies for the treatment of irritable bowel syndrome with diarrhea. Adv Ther. 2020 ; 37: 83-96.
17. Tai DBG, Berbari EF, Suh GA, Lahr BD, Abdel MP, Tande AJ. Truth in DAIR: duration of therapy and the use of quinolone/rifampin-based regimens after debridement and implant retention
for periprosthetic joint infections. Open Forum Infect Dis. 2022; 9: ofac363.
18. Şimşek-Yavuz S, Özger S, Benli A, et al. The Turkish Clinical Microbiology and Infectious Diseases Society (KLİMİK) evidence-based guideline for the diagnosis and treatment of brucellosis,
2023. Klimik Derg. 2023; 36: 86-123.
19. Rotundo S, Tassone MT, Marascio N, et al. A systematic review on antibiotic therapy of cutaneous bacillary angiomatosis not related to major immunocompromising conditions: from pat-
hogenesis to treatment. BMC Infect Dis. 2024; 24: 380.
20. Kadanalı A, Saltoğlu N, Ak Ö, et al. Diagnosis, treatment, prevention, and rehabilitation of diabetic foot ulcers and infections: Turkish Consensus Report, 2024. Klimik Derg. 2024; 37: 1-43.
21. Al-Sudany NK, Ali YJ. Intralesional 8.33% Rifamycin infiltration; new treatment for cutaneous leishmaniasis. J Dermatol Dermatol Surg. 2016; 20: 39-45.
22. Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol. 2020; 15: 1185-1196.
23. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020; 115: 165-178.
24. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America
(IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66: 987-994.
25. Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008; 8: 26.
26. Brandimarte G, Bafutto M, Kruis W, et al. Hot topics in medical treatment of diverticular disease: evidence pro and cons. J Gastrointestin Liver Dis. 2019; 28: 23-29.
27. Goel A, Rahim U, Nguyen LH, Stave C, Nguyen MH. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2017;
46: 1029-1036.
28. Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
MMWR Recomm Rep. 2020; 69: 1-11